Ardelyx Amplified by first hyperphosphataemia success
A win with a tenapanor combo could bode well for the project’s monotherapy chances.
Concert squares up to Pfizer in alopecia Jak bout
Concert believes that high-dose data with CTP-543 will help it challenge Pfizer, but patent questions still loom large.
Second time lucky for Astra in lupus
The extensively overhauled Tulip-2 study of anifrolumab in lupus is an unexpected success.
Astra seeks a survival benefit with its lung triplet
Astrazeneca’s battle with Glaxosmithkline is set to ramp up next year with Breztri Aerosphere mortality data in COPD on the horizon.
Neptune leaves Astra at sea
The Neptune lung cancer study fails, denting yet further Astrazeneca and Bristol-Myers Squibb’s chances of challenging Merck & Co’s Keytruda on the basis of tumour…
Where now for Oxurion?
The failure of its lead product in diabetic macular oedema, a limited pipeline and limited cash leaves Oxurion with few options.
Astra’s Farxiga gets the jump on Jardiance
Astrazeneca gets a win for its SGLT2 in heart failure irrespective of diabetes status, but Lilly and Boehringer’s Jardiance isn’t far behind.
Lynparza’s latest win sets up Astra-Glaxo battle
Success for Lynparza in first-line ovarian cancer, regardless of BRCA mutation status, could see Astrazeneca’s drug regain the upper hand against Glaxosmithkline’s…
Deciphera hopes Invictus win will be just the beginning
Positive data should pave the way for ripretinib’s approval in fourth-line GIST, but investors are already eyeing a bigger opportunity.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.